We are currently conducting a clinical study to establish reference values and reference ranges for ImP in healthy individuals.The aim of the study is to analyze levels of compounds produced by gut bacteria that can be detected in the blood. One such compound is imidazole propionate (ImP), a metabolite produced by the gut microbiota that has been linked to an increased risk of heart attack and stroke. These levels can be measured in blood samples, and elevated concentrations have been shown to predict cardiovascular events several years in advance.

Participants in the study will provide blood samples on two occasions, undergo a simple health examination, and complete questionnaires about their health and dietary habits.

We are recruiting individuals over 18 years of age with a BMI between 17 and 25, who do not have any chronic diseases, are not diabetic, and have not taken antibiotics in the past six months.

The study is conducted at the Institute of Medicine, University of Gothenburg, and the principal investigator is Professor Fredrik Bäckhed.

We are currently able to include more participants. If you would like to learn more, please contact us at RIMI@gu.se.